Optimization of brain targeted chitosan nanoparticles of Rivastigmine for improved efficacy and safety

被引:77
作者
Nagpal, Kalpana [1 ]
Singh, S. K. [1 ]
Mishra, D. N. [1 ]
机构
[1] Guru Jambeshwar Univ Sci & Technol, Dept Pharmaceut Sci, Hisar 125001, Haryana, India
关键词
Chitosan; Elevated plus maze; Maximum tolerated dose; Morris water maze; Optimization; Rivastigmine tartrate; IN-VIVO; ALZHEIMERS-DISEASE; DRUG-DELIVERY; SYSTEM; FORMULATION; DOXORUBICIN; INHIBITION; BARRIER; MEMORY; CELLS;
D O I
10.1016/j.ijbiomac.2013.04.024
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The study aims at formulation and optimization brain targeted nanoparticles (NP) of Rivastigmine (RT) to improve its therapeutic potential and to verify its safety profile. The NP were optimized using a two factor three level (3(2)) central composite design aiming to minimize particle size; maximize zeta potential and drug entrapment efficiency of NP. The optimized formulation (cRTNP) was evaluated using in vitro drug release study; in vivo behavioral, and biochemical and maximum tolerated dose (MTD) study. The optimized formulation evidenced a significant reversal of scopolamine-induced amnesia by Tween 80 (R) coated nanoparticles as compared to both pure RT as well as uncoated nanoparticles. The MTD of RT was increased by 10% by formulating them as cRTNP. Thus, formulation of RT as cRTNP improved the therapeutic and safety profile of RT. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:72 / 83
页数:12
相关论文
共 32 条
[1]  
Amini H, 2010, IRAN J PHARM RES, V9, P115
[2]  
[Anonymous], INVENTI RAPID NDDS
[3]  
[Anonymous], TR490
[4]   Antidepressant-like activity of gallic acid in mice subjected to unpredictable chronic mild stress [J].
Chhillar, Ritu ;
Dhingra, Dinesh .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2013, 27 (04) :409-418
[5]   Biochemical Differentiation of Cholinesterases from Normal and Alzheimer's Disease Cortex [J].
Ciro, Alexis ;
Park, Joon ;
Burkhard, Gary ;
Yan, Nicole ;
Geula, Changiz .
CURRENT ALZHEIMER RESEARCH, 2012, 9 (01) :138-143
[6]   Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting [J].
Fazil, Mohammad ;
Md, Shadab ;
Hague, Shadabul ;
Kumar, Manish ;
Baboota, Sanjula ;
Sahni, Jasjeet Kaur ;
Ali, Javed .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2012, 47 (01) :6-15
[7]   Anaesthetics and postoperative cognitive dysfunction: a pathological mechanism mimicking Alzheimer's disease [J].
Fodale, V. ;
Santamaria, L. B. ;
Schifilliti, D. ;
Mandal, P. K. .
ANAESTHESIA, 2010, 65 (04) :388-395
[8]   Risk assessment for glucosamine and chondroitin sulfate [J].
Hathcock, John N. ;
Shao, Andrew .
REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2007, 47 (01) :78-83
[9]   COMPREHENSIVE OBSERVATIONAL ASSESSMENT .IA. A SYSTEMATIC QUANTITATIVE PROCEDURE FOR ASSESSING BEHAVIORAL AND PHYSIOLOGIC STATE OF MOUSE [J].
IRWIN, S .
PSYCHOPHARMACOLOGIA, 1968, 13 (03) :222-&
[10]   Rivastigmine-loaded PLGA and PBCA nanoparticles: Preparation, optimization, characterization, in vitro and pharmacodynamic studies [J].
Joshi, Shrinidh A. ;
Chavhan, Sandip S. ;
Sawant, Krutika K. .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2010, 76 (02) :189-199